Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative prophylactic therapeutics for rare bleeding and thrombotic disorders. The company's pipeline is built on advanced biological modalities, specifically monoclonal and bispecific antibodies, designed to accumulate, modulate, and utilize endogenous clotting factors to form hemostatic plugs and prevent life-threatening bleeding episodes.
Hemab's lead clinical candidate, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The asset has received Breakthrough Therapy, Fast Track, and Orphan Drug designations from the US FDA. The company's second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 development for the subcutaneous prophylactic treatment of Von Willebrand disease.
As a clinical-stage entity, Hemab is currently pre-revenue and does not generate product sales. Its operations are funded through equity financing, including a successful initial public offering on the Nasdaq in May 2026 that raised over $300 million. Dual-headquartered in Cambridge, Massachusetts, and Copenhagen, Denmark, Hemab leverages its transatlantic presence to access global talent and conduct international clinical trials. The company's competitive position is defined by its focus on highly specialized, underserved hematological indications where existing treatments are often limited to acute interventions or blood transfusions, positioning Hemab as a pioneer in preventative care for these rare conditions.
